PA
Comparison Hub Services

AI Prior Authorization Vendors: Infinitus vs SuperDial vs Neon Health vs Coral AI | Rx Almanac

Head-to-head comparison of four AI-native prior authorization automation vendors targeting different segments of the pharma patient access workflow. Represents the emerging question of where AI ins...

Rx Almanac Research
|

Overview

Prior authorization is one of the most expensive administrative burdens in U.S. healthcare. Physicians spend an average of 13 hours per week on PA work per provider, and more than 94% say PA negatively impacts clinical outcomes. Total drug PA costs are estimated at $93.3 billion per year when accounting for costs absorbed by manufacturers, physicians, and patients.

AI PA spending grew roughly 10x year-over-year, from approximately $10 million in 2024 to $100 million in 2025. The global AI-powered PA market was sized at $1.42 billion in 2024 and is projected to reach $7.12 billion by 2033 at an 18.7% CAGR. Regulatory tailwinds are compounding demand: the CMS Interoperability and Prior Authorization Final Rule sets 2026 compliance deadlines mandating electronic PA APIs with 72-hour urgent and 7-day standard turnaround times.

Within this landscape, four vendors have emerged as distinctive competitors in the AI-native PA automation space: Infinitus Systems, SuperDial, Neon Health, and Coral AI. They reflect fundamentally different architectural bets, market hypotheses, and customer profiles.


Competitor Profiles

Infinitus Systems

Founded in 2019, headquartered in San Francisco. Built the first AI platform specifically designed to automate manual healthcare phone calls. Core insight: the payer system runs primarily on voice (an estimated 3.2 billion healthcare phone calls annually). For pharma, Infinitus focuses on call-intensive hub workflows: benefit verification, PA follow-up, PBM discovery, and formulary exception requests. Eight of the top 10 pharma companies trust Infinitus. Total funding: $102.9M (Series C), led by a16z, Kleiner Perkins, GV/Google Ventures, and Coatue.

SuperDial

Founded late 2023, headquartered in San Francisco. Builds AI agents that make outbound phone calls from providers and billing companies to insurers. Raised $15 million Series A in June 2025 led by SignalFire (total funding $20M+). Acquired voice AI specialist MajorBoost for call-tree navigation. Customer base is primarily RCM companies, dental service organizations, and large provider organizations — not pharma manufacturers or hub services.

Neon Health

Founded in San Francisco, raised a $6 million seed round in September 2025 led by NFX. Positioning is explicitly around specialty drug access for pharma manufacturers. Works with approximately six pharmaceutical brands and has landed CareMetx as a design partner and reference customer. Published case study: 300% ROI within three months, doubled BV throughput, 70% reduction in per-BV labor cost. Differentiation is multi-channel, end-to-end workflow orchestration purpose-built for the specialty Rx journey.

Coral AI

Founded in New York in 2024. Attacks the front-end of the patient access workflow: document intake, eligibility verification, and PA preparation. Seed round led by Lightspeed Venture Partners with participation from leaders at OpenAI and Zapier. Custom-trained models on real healthcare documents capable of reading handwriting, flipped insurance cards, and unstructured text. Processes over 500,000 patient workflows per month across DME providers, infusion centers, and specialty clinics. Customer base is provider-side, not pharma.


Head-to-Head Comparison

At a Glance

DimensionInfinitusSuperDialNeon HealthCoral AI
Founded2019202320242024
Total Funding$102.9M$20M+$6MSeed (Lightspeed)
StageSeries CSeries ASeedSeed
Primary techVoice AI (payer calls)Voice AI (payer calls)Multi-channel AI workersDocument AI + agentic workflows
Primary customerPharma / Hub servicesRCM / ProvidersPharma / Hub servicesProviders (DME, infusion, clinic)
PA workflow stagePost-submission follow-upPost-submission follow-upEnd-to-end (BV through PA through fin. assist.)Pre-submission (intake, prep, drafting)

Technology Architecture

DimensionInfinitusSuperDialNeon HealthCoral AI
Core approachProprietary multimodal AI platform with discrete action space and knowledge graphVoice AI agents + human call center fallbackModular AI workforce: voice, web portal, SMS/fax/email, rules engineDocument AI (CV + ML) for unstructured data; agentic workflow automation
Hallucination controlDiscrete action space limits LLM to approved response set; guardrails at every layerHuman-in-the-loop escalationRules Engine with 100% SOP scoring; human-in-the-loop exceptionsCustom-trained models on real docs; humans review/submit; 98.7% accuracy
Payer interactionVoice AI calls payer, navigates IVR, multi-turn conversationVoice AI calls payer, navigates IVR, talks to repVoice + portal navigation + fax (multi-channel)Primarily portal/document-based
Key claim30% faster calls, 10% higher quality than humans (Cencora)3x cost savings per call, 4x productivity gains98%+ workflows automated, 300% ROI in 3 months (CareMetx)98.7% doc accuracy, 85% PA obtainment rate, 90% workload reduction
ComplianceHIPAA, SOC 2 Type 2, HITRUST Certified CloudHIPAA, SOC 2 Type 2HIPAA compliantHIPAA, payer compliance

Maturity and Scale

DimensionInfinitusSuperDialNeon HealthCoral AI
Years in market~6~2~1~1
Volume100M+ minutes of healthcare conversations; 4M+ calls in knowledge graphTens of thousands of calls per weekNot disclosed500K+ patient workflows/month
Payer coverage1,400+ payers; 1,000+ therapiesNot specifiedNot specifiedNot primarily payer-call-based
Pharma customers8 of top 10 pharmaNot disclosed (primarily providers, RCM)~6 pharma brandsNot disclosed
Hub services customersYes (Amgen SupportPlus, multiple hub partners)No known hub relationshipsCareMetx (design partner / reference)No known hub relationships

Integration Model

DimensionInfinitusSuperDialNeon HealthCoral AI
Hub/PSP roleAugments hub — automates payer call tasksNot designed for hub servicesAugments hub — purpose-built to embed in hub workflowsDoes not target hub services
DeploymentAPI or Infinitus Portal; FastTrack copilot starts without integrationAPI integration with EHR/RCMAPI and CRM/case management integrationEHR integration; adapts to existing workflows
Time to valueFastTrack copilot starts without integration; full API weeksRelatively fastCustom build (weeks to months)Day 1 value

Pricing (Inferred)

VendorPricing ModelNotes
InfinitusPer-call / per-task, enterprise contracts400% ROI framing ($5M return per $1M invested)
SuperDialPer-call pricing50% cost savings vs manual calls documented
Neon HealthCustom / outcome-based per workflow70% cost reduction per BV
Coral AIPer-workflow or subscriptionGrowth metrics suggest volume-based pricing

Use Case Recommendations

When to choose Infinitus

Default choice for mid-to-large pharma manufacturers and hub services organizations needing high-volume payer call automation at proven enterprise scale. 8 of top 10 pharma as customers, knowledge graph from 4M+ calls, 1,400+ payers, 1,000+ therapies, and $102.9M from top-tier VCs make it the most battle-tested option.

Best for:

  • Hub services operations managing BV and PA follow-up calls for specialty medications
  • Proven performance at scale across hundreds of payers
  • Post-submission PA follow-up tracking automation
  • FastTrack copilot mode for IVR bypass without full integration
  • Maximum compliance/hallucination control requirements

Weakness: Not a pre-submission or PA initiation tool. Voice-first — lacks portal automation or multi-channel orchestration.

When to choose Neon Health

Strongest choice for hub services organizations wanting end-to-end workflow automation across the full specialty Rx journey. The CareMetx case study (300% ROI, doubled BV throughput, 70% cost reduction) with a top hub platform COO as public reference is a meaningful data point.

Best for:

  • Hub programs with high BV and PA call volume
  • Extending beyond payer calls to patient onboarding, copay enrollment, adherence
  • Multi-channel hubs (portal, phone, fax, SMS) wanting single automation layer
  • Custom workflow requirements

Weakness: Seed stage with six pharma brand customers and $6M raised. Custom-build model means slower time to value versus Infinitus.

When to choose SuperDial

Not purpose-built for pharma manufacturer or hub services workflows. Customers are RCM companies, DSOs, and provider billing teams. Not the right fit for pharma commercial operations evaluating AI PA for hub or PSP.

Relevant for: specialty pharmacies, infusion centers, or physician practices managing PA calls in-house. Could be a tool for a specialty pharmacy in a manufacturer’s preferred network.

When to choose Coral AI

Not a PA automation vendor in the pharma hub services sense. Value is in pre-submission: reading messy referral packets, extracting data, checking eligibility, drafting PA requests. Customers are DME providers, infusion centers, specialty clinics.

Relevant to pharma if: building or operating a hub that handles inbound referral documents from providers. Could layer in before handing off to a voice AI tool like Infinitus or Neon Health.


Verdict

Vendor Strength/Weakness Summary

VendorStrongest AtWeakest At
InfinitusPayer call automation at scale; pharma/hub use cases; compliance; breadth (1,400+ payers, 1,000+ therapies)Pre-submission PA prep; multi-channel orchestration beyond voice
SuperDialProvider-side RCM call automation; cost-per-call economicsPharma/hub services fit; specialty therapy knowledge
Neon HealthEnd-to-end patient access workflows; hub services fit; multi-channel; CareMetx referenceEarly stage; limited scale data; custom-build model slows deployment
Coral AIPre-submission document intake and PA preparation; unstructured document handlingPayer call automation; pharma/hub fit; specialty therapy depth

Overall Recommendation for Pharma Commercial Operations

Go with Infinitus if you need proven enterprise-scale payer call automation today. The track record across 8 of the top 10 pharma companies, payer and therapy knowledge depth, and compliance architecture maturity are unmatched. The 400% ROI and Cencora metrics are the most independently credible in this group.

Shortlist Neon Health as a strategic alternative or complement — particularly for end-to-end hub workflow automation beyond payer calls. The CareMetx partnership signals strong product-market fit. Accept early-customer risk and negotiate accordingly.

Avoid SuperDial and Coral AI for pharma hub services PA workflows — not because they are weak products, but because they are built for different buyers. Both could become relevant as point solutions (Coral for document intake; SuperDial for SP-side RCM).

The competitive picture will shift as Neon Health scales. If it raises a meaningful Series A, it will be a genuine challenger to Infinitus for new hub program mandates.


Vendor Profiles

Category Pages

Concept Pages

  • Prior Authorization
  • Hub Services Overview
  • Patient Access Journey

Frequently Asked Questions

What are the best AI prior authorization tools for pharma?

For pharma manufacturers and hub services, Infinitus Systems is the proven leader with 8 of the top 10 pharma companies as customers, $102.9M in funding, and a knowledge graph from 4M+ payer calls across 1,400+ payers and 1,000+ therapies. Neon Health is the strongest emerging alternative for end-to-end hub workflow automation, with a CareMetx design partnership demonstrating 300% ROI and 70% cost reduction per benefit verification. SuperDial and Coral AI serve provider-side and RCM use cases rather than pharma hub services.

How much can AI reduce prior authorization costs?

AI PA automation delivers significant cost savings across the workflow. Infinitus reports 400% ROI ($5M return per $1M invested) and 30% faster calls with 10% higher quality than human agents. Neon Health's CareMetx case study shows 300% ROI within three months, doubled BV throughput, and 70% reduction in per-BV labor cost. SuperDial documents 3x cost savings per call and 4x productivity gains on the provider side. Total drug PA costs are estimated at $93.3 billion per year across the system, creating massive savings potential.

What is the CMS prior authorization rule and how does it affect pharma?

The CMS Interoperability and Prior Authorization Final Rule sets 2026 compliance deadlines mandating electronic PA APIs with 72-hour urgent and 7-day standard turnaround times. This regulatory tailwind is accelerating adoption of AI PA tools, with AI PA spending growing roughly 10x year-over-year from approximately $10M in 2024 to $100M in 2025. The global AI-powered PA market is projected to reach $7.12 billion by 2033 at an 18.7% CAGR.

Should pharma companies use Infinitus or Neon Health for AI prior authorization?

Infinitus is the safer choice for enterprises needing proven, high-scale payer call automation today, with 6 years in market, HITRUST certification, and deep payer coverage. Neon Health is the stronger choice for hub organizations wanting end-to-end workflow automation beyond just payer calls, covering BV through PA through financial assistance across voice, portal, fax, and SMS channels. Many programs may benefit from both: Neon Health for multi-channel orchestration and Infinitus for high-volume voice automation at scale.